文献速递头颈部肿瘤放疗

TP53进化作用评分分析:来自2期临床试验NRG肿瘤学放射治疗肿瘤组0234的病理学高危人乳头瘤病毒阴性头颈癌

Evolutionary Action Score of TP53 Analysis in Pathologically High-Risk Human Papillomavirus-Negative Head and Neck Cancer From a Phase 2 Clinical Trial: NRG Oncology Radiation Therapy Oncology Group 0234.
PubMed 文献 · Adv Radiat Oncol · 2022-05-18

本研究对81例经手术治疗的III或IV期人乳头瘤病毒阴性头颈鳞癌且具有高危病理特征患者的切除样本进行TP53靶向测序和进化作用评分(EAp53),患者在接受放疗+西妥昔单抗+顺铂或多西他赛辅助治疗的2期试验中。中位随访9.8年,EAp53分组与治疗对总生存、无病生存和远处转移存在显著交互作用;在野生型或低风险组,多西他赛组的总生存、无病生存和远处转移均显著优于顺铂组,而在高风险或其他组两治疗间差异无统计学意义。

要点

  • 在EAp53野生型或低风险组,多西他赛组较顺铂组总生存更优(HR 0.11)。
  • 在EAp53野生型或低风险组,多西他赛组较顺铂组无病生存更优(HR 0.24)。
  • 在EAp53高风险或其他组,两治疗间差异无统计学意义。

核心结论

  • 对于EAp53野生型或低风险的患者,多西他赛组较顺铂组与更好的生存相关,这些获益似乎主要由远处转移减少驱动。

研究设计与样本

  • 研究纳入81例经手术治疗的III或IV期人乳头瘤病毒阴性头颈鳞癌且具有高危病理特征患者的切除样本,患者来自一项2期研究,接受放疗+西妥昔单抗+顺铂(顺铂组)或放疗+西妥昔单抗+多西他赛(多西他赛组)辅助治疗。
  • 对样本进行TP53靶向测序和EAp53评分,因样本量有限,将患者合并为2组:野生型或低风险组、高风险或其他组。

主要发现

  • 中位随访9.8年,EAp53分组与治疗对总生存存在显著交互作用(P = .008),对无病生存存在显著交互作用(P = .05),对远处转移存在显著交互作用(P = .004)。
  • 在高风险或其他组,两治疗间差异无统计学意义。

关键数值与推荐

  • EAp53分组与治疗对总生存的交互作用P = .008,对无病生存的交互作用P = .05,对远处转移的交互作用P = .004。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: An evolutionary action scoring algorithm (EAp53) based on phylogenetic sequence variations stratifies patients with head and neck squamous cell carcinoma (HNSCC) bearing TP53 missense mutations as high-risk, associated with poor outcomes, or low-risk, with similar outcomes as TP53 wild-type, and has been validated as a reliable prognostic marker. We performed this study to further validate prior findings demonstrating that EAp53 is a prognostic marker for patients with locally advanced HNSCC and explored its predictive value for treatment outcomes to adjuvant bio-chemoradiotherapy. METHODS AND MATERIALS: Eighty-one resection samples from patients treated surgically for stage III or IV human papillomavirus-negative HNSCC with high-risk pathologic features, who received either radiation therapy + cetuximab + cisplatin (cisplatin) or radiation therapy + cetuximab + docetaxel (docetaxel) as adjuvant treatment in a phase 2 study were subjected to TP53 targeted sequencing and EAp53 scoring to correlate with clinical outcomes. Due to the limited sample size, patients were combined into 2 EAp53 groups: (1) wild-type or low-risk; and (2) high-risk or other. RESULTS: At a median follow-up of 9.8 years, there was a significant interaction between EAp53 group and treatment for overall survival (P = .008), disease-free survival (P = .05), and distant metastasis (DM; P = .004). In wild-type or low-risk group, the docetaxel arm showed significantly better overall survival (hazard ratio [HR] 0.11, [0.03-0.36]), disease-free survival (HR 0.24, [0.09-0.61]), and less DM (HR 0.04, [0.01-0.31]) than the cisplatin arm. In high-risk or other group, differences between treatments were not statistically significant. CONCLUSIONS: The docetaxel arm was associated with better survival than the cisplatin arm for patients with wild-type or low-risk EAp53. These benefits appear to be largely driven by a reduction in DM.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Michikawa C, Torres-Saavedra PA, Silver NL, et al. Evolutionary Action Score of TP53 Analysis in Pathologically High-Risk Human Papillomavirus-Negative Head and Neck Cancer From a Phase 2 Clinical Trial: NRG Oncology Radiation Therapy Oncology Group 0234. Adv Radiat Oncol. 2022. PMID: 36420184. doi:10.1016/j.adro.2022.100989

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。